Cardio Diagnostics Schedules Dec. 10 Investor Call to Detail FDA Breakthrough Device Plans and NOCAD Detection Strategy

Cardio Diagnostics Holdings will host a Dec. 10 investor call to outline its FDA Breakthrough Device designation strategy, non-obstructive coronary artery disease detection data, and international expansion into India, highlighting the growing role of AI-driven blood tests in cardiovascular risk assessment.

Chicago Metrowire Staff
••Healthcare
Cardio Diagnostics Schedules Dec. 10 Investor Call to Detail FDA Breakthrough Device Plans and NOCAD Detection Strategy

Cardio Diagnostics Holdings (NASDAQ: CDIO) has scheduled an investor conference call for Dec. 10, 2026, at 11 a.m. CT, where management will present updates on its precision cardiovascular disease detection technologies and outline plans to seek U.S. Food and Drug Administration Breakthrough Device designation. The announcement matters because it signals a potential regulatory milestone for the company’s blood-based approach to identifying non-obstructive coronary artery disease, a condition that conventional diagnostic methods can miss.

The call will cover the company’s commercially available Epi+Gen CHD(TM) and PrecisionCHD(TM) tests, along with updates on ongoing and planned studies, reimbursement progress and strategic growth initiatives. Management plans to present data supporting its blood-based technology for detecting non-obstructive coronary artery disease, or NOCAD. The emphasis on NOCAD is significant: patients with this condition may not show the obvious blockages that standard tests detect, yet they remain at risk, so a scalable blood test could fill a diagnostic gap that affects both clinical decision-making and payer calculations.

Cardio Diagnostics’ approach combines epigenetics, genetics and artificial intelligence to provide scalable cardiovascular risk assessment and early disease detection through standard blood samples. If the company’s data support its case, the anticipated FDA Breakthrough Device request could accelerate review and positioning for its technology, which would have implications for how cardiovascular risk is assessed in routine care. The investor call is also expected to address the commencement of testing in India, Cardio Diagnostics’ first international market, through partnerships with Dr. Lal PathLabs and Aimil. That international step matters because it tests whether the company’s model can scale beyond the U.S. market and reach larger patient populations through established lab networks.

For investors, the Dec. 10 call offers a consolidated view of study progress, reimbursement developments and growth strategy at a time when cardiovascular diagnostics are attracting attention for their potential to improve early detection. The full press release is available at https://ibn.fm/tEHRV, and the latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.

The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services, including editorial syndication to 5,000+ outlets. The broader implication is that Cardio Diagnostics is using a visible investor forum to tie its clinical data, regulatory ambitions and international expansion into a single narrative, giving shareholders and clinicians a clearer picture of how quickly its AI-driven cardiovascular tests could move from commercial availability to mainstream adoption.

Blockchain Registration

QR Code for Blockchain Registration